Products and methods for treating muscular dystrophy

U7snRNA vectors targeting exons 6, 7, and 9 in the DMD gene restore the reading frame, enhancing dystrophin expression and improving muscle function in patients with muscular dystrophy.

JP7948958B2Active Publication Date: 2026-11-11RES INST AT NATIONWIDE CHILDRENS HOSPITAL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023564657
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-04-23
Filing Date
2022-04-22
Publication Date
2026-11-11
Estimated Expiration
2042-04-22

Smart Images

  • Figure 0007948958000009
    Figure 0007948958000009
  • Figure 0007948958000010
    Figure 0007948958000010
  • Figure 0007948958000011
    Figure 0007948958000011
Patent Text Reader

Abstract

Products and methods are provided for treating or preventing muscular dystrophy in patients with mutations in any of exons 6, 7, 8, or 9 in the DMD gene. Gene therapy vectors, such as adeno-associated virus (AAV) vectors, and methods of using these vectors to deliver nucleic acids containing DMD antisense sequences in modulating or restoring expression of the transcript of the DMD gene and a functional form of the dystrophin protein, are provided. The products and methods are used to treat, ameliorate, and / or prevent muscular dystrophy, such as Duchenne muscular dystrophy or Becker muscular dystrophy.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • US90,3710-37141993

  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof

    WO2006000057A1

  • Compositions and methods for correcting dystrophin mutations in human cardiomyocytes

    WO2019152609A1

  • Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies

    WO2021026075A1